Heat Biologics (HTBX +0.2%) has submitted a revised protocol with the FDA for the Phase II trial of the company's HS-110 drug for the treatment of non-small cell lung cancer (NSCLC).
HS-110 utilizes genetically modified lung-cancer cells to stimulate a patient's immune system against a wide array of lung-cancer antigens.
Heat plans to start the study in Q3 and enroll 120 patient. The endpoints will include overall survival rates. (PR)